Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

mRNA and gene editing: Late breaking therapies in liver diseases
Nerea Zabaleta, Laura Torella, Nicholas D. Weber, et al.
Hepatology (2022) Vol. 76, Iss. 3, pp. 869-887
Open Access | Times Cited: 24

Showing 24 citing articles:

Combinatorial development of nebulized mRNA delivery formulations for the lungs
Allen Yujie Jiang, Jacob Witten, Idris O. Raji, et al.
Nature Nanotechnology (2023) Vol. 19, Iss. 3, pp. 364-375
Open Access | Times Cited: 60
Antioxidant and anti-inflammatory agents in chronic liver diseases: Molecular mechanisms and therapy
Chunye Zhang, Shuai Liu, Ming Yang
World Journal of Hepatology (2023) Vol. 15, Iss. 2, pp. 180-200
Open Access | Times Cited: 45
A new age of precision gene therapy
Axel Schambach, Christian J. Buchholz, Raúl Torres, et al.
The Lancet (2023) Vol. 403, Iss. 10426, pp. 568-582
Closed Access | Times Cited: 45
Interim analyses of a first-in-human phase 1/2 mRNA trial for propionic acidaemia
Dwight D. Koeberl, Andreas Schulze, Neal Sondheimer, et al.
Nature (2024) Vol. 628, Iss. 8009, pp. 872-877
Open Access | Times Cited: 41
High-density brush-shaped polymer lipids reduce anti-PEG antibody binding for repeated administration of mRNA therapeutics
Yufen Xiao, Xizhen Lian, Yehui Sun, et al.
Nature Materials (2025)
Closed Access | Times Cited: 4
Molecular mechanisms in liver repair and regeneration: from physiology to therapeutics
Xiao Ma, Tengda Huang, Xi Chen, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 2
Gene editing therapeutics based on mRNA delivery
Juliana Popovitz, Rohit Sharma, Reyhane Hoshyar, et al.
Advanced Drug Delivery Reviews (2023) Vol. 200, pp. 115026-115026
Open Access | Times Cited: 28
Optimizing 5’UTRs for mRNA-delivered gene editing using deep learning
Sebastian M. Castillo-Hair, Stephen Fedak, Ban Wang, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 16
Targeted delivery strategies: The interactions and applications of nanoparticles in liver diseases
Xiandi Meng, Ge Zhu, Yong‐Guang Yang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 175, pp. 116702-116702
Open Access | Times Cited: 9
Cell therapy for liver disorders: past, present and future
María del Carmen Ortuño‐Costela, Massimo Pinzani, Ludovic Vallier
Nature Reviews Gastroenterology & Hepatology (2025)
Closed Access
Targeting Polymeric Nanoparticles to Specific Cell Populations in the Liver
Lauren Harkins, Sílvia Vilarinho, W. Mark Saltzman
Biochemistry (2025)
Closed Access
Delivery of Synthetic Interleukin‐22 mRNA to Hepatocytes via Lipid Nanoparticles Alleviates Liver Injury
Hanxiang Ouyang, Shenyu Wei, Bingqiang Gao, et al.
Small (2024) Vol. 20, Iss. 45
Closed Access | Times Cited: 3
How far are the new wave of mRNA drugs from us? mRNA product current perspective and future development
Qiongyu Duan, Tianyu Hu, Qiuxia Zhu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 13
mRNA-Based Approaches to Treating Liver Diseases
Maximiliano L. Cacicedo, María J. Limeres, Stephan Gehring
Cells (2022) Vol. 11, Iss. 20, pp. 3328-3328
Open Access | Times Cited: 12
Gene editing in liver diseases
Laura Torella, Nerea Santana‐Gonzalez, Nerea Zabaleta, et al.
FEBS Letters (2024)
Open Access | Times Cited: 2
Gene therapy for polygenic or complex diseases
Tingting Wu, Yu Hu, Liang Tang
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 2
The future of hepatology – “The best way to predict the future is to create it”
Thomas Berg, Aleksander Krag
Journal of Hepatology (2023) Vol. 79, Iss. 2, pp. 253-260
Closed Access | Times Cited: 5
Co-administration of an effector antibody enhances the half-life and therapeutic potential of RNA-encoded nanobodies
Moritz Thran, Marion Pönisch, Hillary Danz, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 5
Gene Therapies in the Fight against Liver Disease: A Comprehensive Review
Phillip Leff, Majd B. Aboona, Silpa Choday, et al.
Journal of Advances in Medicine and Medical Research (2024) Vol. 36, Iss. 5, pp. 38-58
Open Access | Times Cited: 1
IL-22: A key inflammatory mediator as a biomarker and potential therapeutic target for lung cancer
Ling Xu, Peng Cao, Jianpeng Wang, et al.
Heliyon (2024) Vol. 10, Iss. 17, pp. e35901-e35901
Open Access | Times Cited: 1
Optimizing 5’UTRs for mRNA-delivered gene editing using deep learning
Sebastian M. Castillo-Hair, Stephen Fedak, Ban Wang, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 2
Prevalence and Associated Factors of Liver Disease among Adults: A cross–sectional study at a Health facility in North-Eastern Part of Ghana
Patrick Adolgo
Epidemiology International Journal (2023) Vol. 7, Iss. 3, pp. 1-8
Open Access | Times Cited: 1
Prime Editing in Mammals: The Next Generation of Precision Genome Editing
Dawei Wang, Xiude Fan, Mengzhu Li, et al.
The CRISPR Journal (2022) Vol. 5, Iss. 6, pp. 746-768
Closed Access | Times Cited: 2
Page 1

Scroll to top